全球桑格定序市场

预计 2030 年全球桑格定序市场规模将达 89 亿美元

全球桑格定序市场规模预计在2024年为34亿美元，预计到2030年将达到89亿美元，2024年至2030年的复合年增长率为17.5%。报告分析的细分市场之一—霰弹枪定序，预计其复合年增长率为16.3%，到分析期结束时规模将达到54亿美元。标靶基因定序细分市场在分析期间的复合年增长率估计为19.1%。

美国市场规模估计为 8.942 亿美元，中国市场预计复合年增长率为 16.6%

预计到2024年，美国桑格定序市场规模将达到8.942亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到14亿美元，在2024-2030年的分析期间内，复合年增长率为16.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为15.9%和15.3%。在欧洲，预计德国市场的复合年增长率约为13.0%。

全球「桑格定序」市场—主要趋势与驱动因素摘要

为什么桑格定序在基因组学主导的世界中仍然很重要？

儘管新一代定序 (NGS) 平台兴起，桑格定序仍因其无与伦比的准确性、简便性和在某些应用方面的成本效益而保持着其相关性。它仍然是序列检验、单基因诊断和小型研究计划的黄金标准。此方法在临床基因组学中受到高度重视，用于确认透过高通量方法发现的变异。桑格定序受到研究人员的青睐，因为它可以提供长、高保真读取，通常跨越多达 1000 个碱基对，使其成为检测目标区域中插入、缺失和突变的理想选择。在诊断实验室中，它被广泛用于罕见和遗传疾病的基因检测。桑格的最小资料输出简化了储存和分析，特别是在资源有限的环境中。与复杂的 NGS 工作流程相比，它还具有更快的周转时间。随着基因组学市场多元化到兽医、农业和微生物学领域，桑格定序的稳健性使其成为必不可少的补充技术。毛细管电泳系统的适应性及其与现有实验室基础设施整合的能力继续支持其在传统和新兴使用案例使用案例中的应用。

科技如何让桑格定序更加精准方便？

最近的进展显着改善了桑格定序工作流程，降低了成本并提高了通量。 DNA萃取、PCR纯化和反应製备的自动化最大限度地减少了人为错误，并提高了样品处理的效率。染料终止剂化学和毛细管电泳系统的改进提高了讯号清晰度、速度和数据解析度。紧凑型桌上型定序仪使小型实验室和诊所能够进行分散式定序，与云端基础生物资讯平台的整合使非专业人士也能进行数据分析、解读和报告。人工智慧工具正被用于更可靠地检测低频变异。试剂的微型化有助于降低每个样本的成本，开放原始码实验室设备正在促进学术机构低成本地采用该技术。样本的条码标记实现了更高水准的多重分析，从而提高了实验室的生产效率。此外，即时监控工具确保了每个阶段的品管。因此，桑格定序不再只是一个手动的实验室程序，而正在演变成一个半自动化的智慧平台，可以完美地融入更广泛的基因组学生态系统。

哪里对桑格定序的需求成长最快？

在某些注重准确性和确认性的行业中，桑格定序正迎来新的需求。在临床诊断中，它常用于种系突变的确认性检测，尤其是在癌症易感性和罕见疾病检测中。在药物基因组学中，准确的基因型鉴定对于个人化治疗至关重要，其作用正在扩大。农业基因组学也是一个不断发展的领域，桑格定序被用于作物基因分型、性状确认和育种计画。在微生物学中，它用于病原体鑑定、抗生素抗药性分析和质体检验。兽医学越来越多地采用桑格测序对纯种动物进行基因筛检和疾病追踪。由于其高品质的读取输出，法医学实验室继续使用这种方法进行线粒体 DNA 分析。由于桑格系统可靠且易于使用，教育机构也在利用它来培训学生定序基础知识。越来越多地将定序服务外包给合约研究组织 (CRO)，进一步推动了市场稳定的需求。这些特定领域的要求凸显了桑格作为现代基因组学基础技术的独特作用。

桑格定序市场的成长受到多种因素的推动...

桑格测序市场的扩张受到持久技术吸引力和不断变化的行业需求共同推动。临床诊断对可靠确认测试的需求使其使用得以维持，特别是随着伴随诊断在精准医疗中变得越来越普遍。学术机构和政府机构越来越多的研究倡议也在刺激市场扩张。成本效益和易于设置使桑格成为低通量实验室的首选方法，特别是在发展中地区。 NGS 资料集的日益复杂性导致人们越来越依赖桑格定序进行最终验证。监管机构更喜欢使用桑格数据进行审批，因为它具有已验证的可重复性和准确性。对实验室自动化和桌上型定序仪器的持续投资使该技术具有扩充性。此外，市场还受益于医院、CRO 和分子诊断公司之间日益增长的合作。桑格测序作为从感染疾病监测到植物育种等各种基因组套件包的补充解决方案而蓬勃发展。

部分

类型（霰弹枪定序、标靶基因定序、其他类型）；应用（诊断、个人化医疗、法医学、其他应用）；最终用途（政府研究机构、诊断实验室、製药和生物技术公司、其他最终用途）

受访企业范例（共42家）

• AAT Bioquest
• Azenta Life Sciences（GENEWIZ）
• BaseClear
• BGI Genomics
• Eurofins Genomics
• GenScript
• Illumina
• LGC Biosearch Technologies
• Macrogen
• MCLAB
• Microsynth AG
• Nucleics
• Psomagen
• QIAGEN
• Roche Applied Science
• SeqLab
• Source BioScience
• Synlab
• Thermo Fisher Scientific
• Zymo Research

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 其他欧洲国家
• 亚太地区
• 其他地区

第四章 比赛

Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030

The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR

The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.

Global "Sanger Sequencing" Market - Key Trends & Drivers Summarized

Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?

Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.

How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?

Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.

In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?

Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it's frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.

The Growth In The Sanger Sequencing Market Is Driven By Several Factors...

The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.

SCOPE OF STUDY:

The report analyzes the Sanger Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• AAT Bioquest
• Azenta Life Sciences (GENEWIZ)
• BaseClear
• BGI Genomics
• Eurofins Genomics
• GenScript
• Illumina
• LGC Biosearch Technologies
• Macrogen
• MCLAB
• Microsynth AG
• Nucleics
• Psomagen
• QIAGEN
• Roche Applied Science
• SeqLab
• Source BioScience
• Synlab
• Thermo Fisher Scientific
• Zymo Research

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Sanger Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Continued Use in Targeted DNA Sequencing Applications Sustains Demand for Sanger Sequencing
  • Clinical Diagnostics and Genetic Validation Workflows Strengthen Business Case for Precision Sequencing
  • Pharma and Biotech R&D Activities Throw the Spotlight on Sangers Reliability in Mutation Detection
  • Growing Preference for Low-Throughput, High-Accuracy Techniques in Niche Applications Drives Adoption
  • Cost-Effectiveness in Academic and Clinical Labs Sustains Long-Term Relevance of Sanger Platforms
  • Rising Prevalence of Genetic Disorders Accelerates Use in Confirmatory Testing
  • Expansion of Outsourced Sequencing Services Creates New Demand from Research Institutions
  • Next-Generation Sequencing Limitations in Long Homopolymer Regions Create Opportunities for Sanger
  • Regulatory Compliance in Clinical Genomics Favors Established and Validated Technologies
  • Integration with NGS Workflows for Hybrid Pipelines Expands Market Potential
  • Low Entry Cost and Training Requirements Sustain Adoption in Emerging Markets and Universities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sanger Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Shotgun Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Shotgun Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Targeted Gene Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Targeted Gene Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Forensics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Forensics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 30: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 36: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• JAPAN
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 42: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• CHINA
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 48: China Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• EUROPE
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• FRANCE
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 58: France Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• GERMANY
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• ITALY
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• UNITED KINGDOM
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 76: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• ASIA-PACIFIC
  • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030

IV. COMPETITION